A Placebo-Controlled Trial of Atomoxetine in Marijuana-Dependent Individuals with Attention Deficit Hyperactivity Disorder

被引：59
|
作者：
McRae-Clark, Aimee L. [1 ]
Carter, Rickey E. [2 ]
Killeen, Therese K. [1 ]
Carpenter, Matthew J. [1 ]
White, Kathleen G. [1 ]
Brady, Kathleen T. [1 ]
机构：
[1] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA
[2] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA
来源：
AMERICAN JOURNAL ON ADDICTIONS | 2010年 / 19卷 / 06期
关键词：
DEFICIT/HYPERACTIVITY DISORDER; SUBSTANCE-ABUSE; ADULT ADHD; SUBTHRESHOLD DIAGNOSES; LATE-ONSET; FOLLOW-UP; ALCOHOL; METHYLPHENIDATE; COMORBIDITY; COGNITION;
D O I：
10.1111/j.1521-0391.2010.00076.x
中图分类号：
R194 [卫生标准、卫生检查、医药管理];
学科分类号：
摘要：
This study evaluated the effects of atomoxetine on the symptoms of attention deficit hyperactivity disorder (ADHD) and marijuana use in marijuana-dependent adults. In conjunction with motivational interviewing, participants received either atomoxetine (n = 19) or matching placebo (n = 19) for 12 weeks. Participants randomized to atomoxetine had greater improvement in ADHD on the Clinical Global Impression-Improvement scale than participants treated with placebo. No treatment group differences in self-rated ADHD symptoms, overall Wender-Reimherr Adult Attention Deficit Disorder Scale scores, or marijuana use outcomes were noted. These results suggest that atomoxetine may improve some ADHD symptoms but does not reduce marijuana use in this population. (Am J Addict 2010;00:1-9).
引用
收藏
页码：481 / 489
页数：9
相关论文
共 50 条
  • [21] Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study
    Michelson, D
    Faries, D
    Wernicke, J
    Kelsey, D
    Kendrick, K
    Sallee, FR
    Spencer, T
    PEDIATRICS, 2001, 108 (05) : E83
  • [22] Effect of Atomoxetine Treatment on Reading and Phonological Skills in Children with Dyslexia or Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia in a Randomized, Placebo-Controlled Trial
    Shaywitz, Sally
    Shaywitz, Bennett
    Wietecha, Linda
    Wigal, Sharon
    McBurnett, Keith
    Williams, David
    Kronenberger, William G.
    Hooper, Stephen R.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2017, 27 (01) : 19 - 28
  • [23] Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia
    Martenyi, Ferenc
    Zavadenko, Nikolay N.
    Jarkova, Natalia B.
    Yarosh, Alexandr A.
    Soldatenkova, Victoria O.
    Bardenstein, Leonid M.
    Kozlova, Irina A.
    Neznanov, Nikolay G.
    Maslova, Olga I.
    Petrukhin, Andrey S.
    Sukchotina, Nina K.
    Zykov, Valeriy P.
    EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2010, 19 (01) : 57 - 66
  • [24] Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia
    Ferenc Martenyi
    Nikolay N. Zavadenko
    Natalia B. Jarkova
    Alexandr A. Yarosh
    Victoria O. Soldatenkova
    Leonid M. Bardenstein
    Irina A. Kozlova
    Nikolay G. Neznanov
    Olga I. Maslova
    Andrey S. Petrukhin
    Nina K. Sukchotina
    Valeriy P. Zykov
    European Child & Adolescent Psychiatry, 2010, 19 : 57 - 66
  • [25] Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study
    Dell'Agnello, Grazia
    Maschietto, Dino
    Bravaccio, Carmela
    Calamoneri, Filippo
    Masi, Gabriele
    Curatolo, Paolo
    Besana, Dante
    Mancini, Francesca
    Rossi, Andrea
    Poole, Lynne
    Escobar, Rodrigo
    Zuddas, Alessandro
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 (11) : 822 - 834
  • [26] Atomoxetine Treatment of Attention-Deficit/Hyperactivity Disorder in Young Adults With Assessment of Functional Outcomes A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Durell, Todd M.
    Adler, Lenard A.
    Williams, Dave W.
    Deldar, Ahmed
    McGough, James J.
    Glaser, Paul E.
    Rubin, Richard L.
    Pigott, Teresa A.
    Sarkis, Elias H.
    Fox, Bethany K.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2013, 33 (01) : 45 - 54
  • [27] Executive function in adult patients with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled withdrawal study
    Goto, T.
    Adler, L.
    Upadhyaya, H.
    Trzepacz, P.
    Tanaka, Y.
    Williams, D.
    Heinloth, A.
    Allen, A.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 220 - 220
  • [28] Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: A prospective, placebo-controlled assessment
    Wernicke, JF
    Adler, L
    Spencer, T
    West, SA
    Allen, AJ
    Heiligenstein, J
    Milton, D
    Ruff, D
    Brown, WJ
    Kelsey, D
    Michelson, D
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2004, 24 (01) : 30 - 35
  • [29] Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children
    Biederman, Joseph
    Gao, Haitao
    Rogers, Ann K.
    Spencer, Thomas J.
    BIOLOGICAL PSYCHIATRY, 2006, 60 (10) : 1106 - 1110
  • [30] A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder
    Kahbazi, Manijeh
    Ghoreishi, Aboulfazl
    Rahiminejad, Fatemeh
    Mohammadi, Mohammad-Reza
    Kamalipour, Abbas
    Akhondzadeh, Shahin
    PSYCHIATRY RESEARCH, 2009, 168 (03) : 234 - 237
12345